A/Pr Julie Atkin
Cellular transport dysfunction and motor neuron disease
National Health and Medical Research Council
Amyotrophic lateral sclerosis (ALS) patients currently face a bleak future. In the common global form of disease, the average length of survival after diagnosis is 31 months. Current therapies have at best a modest effect on the course of the disease with little or no benefit in terms of overall patient survival. This study will address the basic underlying biochemical mechanisms of disease in both sporadic and genetic forms of ALS. This studies will lead to opportunities to develop new therapies in the future.